Shanghai Industrial Zone Operational

14 July 1996

- The recently-constructed Shanghai Industrial Zone went into operation in Pudong at the beginning of June. The establishment of this zone will step up the transformation of the R&D achievement of bio-engineering medicine to industrialization and promote the development of the modern biotechnology industry in China.

The first batch of research institutes and their industrialized products are listed below: -------------------------------------------------------------------------- Shanghai Huaxin Bio High-Tech Co IL-2 and IFN alfa 2b Shanghai Lianhe Saier hGH Bio-Engineering Co Shanghai Shiye Bio-Tech Co rSK Shanghai Sanwei Bio-Tech Co G-CSF --------------------------------------------------------------------------

The first stage of the project will be completed by the year 1997, and the second stage by the year 2000. Sales are expected to be around $120 million by then.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight